Please Wait.....
Report
Japan Dry Eye Disease Market Forecast 2024-2032
Market Report I 2024-10-12 I 143 Pages I Inkwood Research
KEY FINDINGS
The Japan dry eye disease market is projected to grow at a CAGR of 5.26% from 2024 to 2032. The market was valued at $251.44 million in 2023, reaching an expected revenue of $401.68 million by 2032. The rising prevalence of dry eye diseases in Japan is linked to modern lifestyle factors such as increased screen exposure and environmental pollution, which significantly contribute to the incidence of dry eye disease symptoms. The growing geriatric population also plays a key role, as older individuals are more susceptible to dry eye diseases due to age-related reduction in tear production.
MARKET INSIGHTS
Rising awareness about dry eye disease and its symptoms, coupled with improved access to treatments, has significantly expanded the market in Japan. The growing prevalence of chronic conditions such as diabetes and autoimmune disorders, which are known causes of dry eye disease, has also increased the patient base. Furthermore, two cross-sectional, population-based studies evaluated the epidemiology of dry eye disease (DED) in Japan and found that its prevalence in the Japanese population was higher compared to other countries.
The most commonly prescribed treatments for dry eye in Japan are the 3% diquafosol ophthalmic solution (Diquas; Santen Pharmaceutical Co., Ltd, Osaka, Japan), available since 2010, which directly stimulates aqueous and mucous secretion on the ocular surface, and the 2% rebamipide ophthalmic suspension (Mucosta; Otsuka Pharmaceutical Co Ltd, Tokyo, Japan), available since 2012.
Furthermore, according to a study titled 'Medical Treatment for Dry Eye in Japan, ' sodium hyaluronate ophthalmic solutions have been used for many years in combination with preservative-free artificial tear solutions to treat dry eyes. The same study also highlighted the economic burden associated with DED in Japan, estimating the annual health plan cost per patient at $323.
Additionally, productivity losses per patient due to DED ranged from $741 to $6,160, underscoring the significant economic impact of the condition across generations in the Japanese population. This economic burden further drives the market's growth, as it emphasizes the need for effective treatment options. Additional factors such as technological advancements, research and development efforts, government initiatives, and the growing prevalence of dry eye disease are expected to propel the market in Japan. As a result, the market is anticipated to grow significantly throughout the forecast period.
SEGMENTATION ANALYSIS
The Japan dry eye disease market segmentation includes distribution channel, type, dosage, and product. The dosage segment is further classified into eye drops, eye solutions, ointments, gels, and capsules & tablets.
Eye drops are the most commonly used and effective dosage type for managing and treating dry eye disease. They provide localized relief by directly targeting the ocular surface, delivering hydration, and mimicking natural tears to alleviate symptoms such as irritation, redness, and dryness. Eye drops are available in various formulations, including artificial tears, anti-inflammatory agents, and lubricating gels, to cater to different levels of dry eye severity.
Some eye drops contain active ingredients like sodium hyaluronate, which enhances moisture retention, or ciclosporin, which reduces inflammation and promotes tear production. Preservative-free options are also available to minimize potential irritation, especially for patients with sensitive eyes or those requiring frequent use. Eye drops are convenient, easy to administer, and widely accessible over-the-counter (OTC) or through prescriptions for more specialized formulations. This flexibility and variety make them an essential and preferred treatment method for dry eye disease, suitable for both acute and chronic management.
COMPETITIVE INSIGHTS
Some of the leading companies in the Japan dry eye disease market include Bausch Health Companies Inc, Otsuka Pharmaceutical Co Ltd, Allergan Plc (Acquired by AbbVie), etc.
Otsuka Pharmaceutical Co Ltd operates across various sectors, including pharmaceuticals, nutraceuticals, and consumer products, through its subsidiaries. The company focuses on the development, manufacturing, and sale of medicines for a wide range of conditions, including cancer, ophthalmic diseases, infectious diseases, gastrointestinal and respiratory conditions, and allergies. Its diverse product portfolio encompasses functional foods and beverages, pharmaceutical products, over-the-counter (OTC) items, electronic equipment, and fine chemicals.
Otsuka markets its products across Asia, Europe, and North America, with its headquarters located in Chiyoda-ku, Tokyo, Japan. One of its key products, Mucosta Ophthalmic Suspension, is designed to stabilize the tear film, making it an effective treatment for dry eye disease.
TABLE OF CONTENTS
1. RESEARCH SCOPE & METHODOLOGY
1.1. STUDY OBJECTIVES
1.2. METHODOLOGY
1.3. ASSUMPTIONS & LIMITATIONS
2. EXECUTIVE SUMMARY
2.1. MARKET SIZE & ESTIMATES
2.2. MARKET OVERVIEW
2.3. SCOPE OF STUDY
2.4. CRISIS SCENARIO ANALYSIS
2.4.1. IMPACT OF COVID-19 ON THE DRY EYE DISEASE MARKET
2.5. MAJOR MARKET FINDINGS
2.5.1. PROLONGED SCREEN EXPOSURE CAN TRIGGER SYMPTOMS OF DRY EYE
2.5.2. INDIVIDUALS OF ASIAN DESCENT ARE MORE SUSCEPTIBLE TO DEVELOPING DRY EYE DISEASE
2.5.3. AIR POLLUTION IS A SIGNIFICANT CONTRIBUTOR TO EYE-RELATED CONDITIONS
2.5.4. THE COVID-19 PANDEMIC HAS LED TO A SURGE IN DRY EYE DISEASE CASES
3. MARKET DYNAMICS
3.1. KEY DRIVERS
3.1.1. RISING INCIDENCE AND PREVALENCE OF DRY EYE AMONG VARIOUS AGE GROUPS
3.1.2. LAUNCH OF PIPELINE PRODUCTS FOR THE TREATMENT OF DRY EYE DISEASE
3.1.3. INTRODUCTION OF NEW DIAGNOSTIC TECHNIQUES FOR DRY EYE DISEASE
3.2. KEY RESTRAINTS
3.2.1. RISK OF SIDE EFFECTS ASSOCIATED WITH TREATMENTS
3.2.2. AVAILABILITY OF ALTERNATIVE THERAPIES
3.2.3. HIGH COSTS OF SPECIALTY PRODUCTS AND A COMPLEX REIMBURSEMENT LANDSCAPE
4. KEY ANALYTICS
4.1. PARENT MARKET ANALYSIS
4.2. KEY MARKET TRENDS
4.2.1. EMERGING STEM CELL THERAPY IN THE TREATMENT OF DRY EYE DISEASE
4.3. PORTER'S FIVE FORCES ANALYSIS
4.3.1. BUYERS POWER
4.3.2. SUPPLIERS POWER
4.3.3. SUBSTITUTION
4.3.4. NEW ENTRANTS
4.3.5. INDUSTRY RIVALRY
4.4. GROWTH PROSPECT MAPPING
4.4.1. GROWTH PROSPECT MAPPING FOR JAPAN DRY EYE DISEASE MARKET
4.5. MARKET MATURITY ANALYSIS
4.6. MARKET CONCENTRATION ANALYSIS
4.7. VALUE CHAIN ANALYSIS
4.7.1. RESEARCH AND DEVELOPMENT
4.7.2. MANUFACTURING
4.7.3. DISTRIBUTORS
4.7.4. POST-SALES MONITORING
5. MARKET BY TYPE
5.1. OTC
5.2. PRESCRIPTION
6. MARKET BY PRODUCT
6.1. ANTI-INFLAMMATORY DRUGS
6.1.1. CYCLOSPORINE
6.1.2. CORTICOSTEROID
6.1.3. OTHER ANTI-INFLAMMATORY DRUGS
6.2. ARTIFICIAL TEARS
6.3. PUNCTAL PLUGS
6.4. SECRETAGOGUES
6.5. OTHER PRODUCTS
7. MARKET BY DOSAGE
7.1. EYE DROPS
7.2. EYE SOLUTIONS
7.3. OINTMENTS
7.4. GELS
7.5. CAPSULES & TABLETS
8. MARKET BY DISTRIBUTION CHANNEL
8.1. HOSPITAL PHARMACIES
8.2. INDEPENDENT PHARMACIES AND DRUG STORES
8.3. ONLINE PHARMACIES/STORES
9. COMPETITIVE LANDSCAPE
9.1. KEY STRATEGIC DEVELOPMENTS
9.1.1. MERGERS & ACQUISITIONS
9.1.2. PRODUCT LAUNCHES & DEVELOPMENTS
9.1.3. PARTNERSHIPS & AGREEMENTS
9.1.4. BUSINESS EXPANSIONS & DIVESTITURES
9.2. COMPANY PROFILES
9.2.1. ALLERGAN PLC (ACQUIRED BY ABBVIE)
9.2.1.1. COMPANY OVERVIEW
9.2.1.2. PRODUCT LIST
9.2.1.3. STRENGTHS & CHALLENGES
9.2.2. BAUSCH HEALTH COMPANIES INC
9.2.2.1. COMPANY OVERVIEW
9.2.2.2. PRODUCT LIST
9.2.2.3. STRENGTHS & CHALLENGES
9.2.3. JOHNSON & JOHNSON
9.2.3.1. COMPANY OVERVIEW
9.2.3.2. PRODUCT LIST
9.2.3.3. STRENGTHS & CHALLENGES
9.2.4. OTSUKA PHARMACEUTICAL CO LTD
9.2.4.1. COMPANY OVERVIEW
9.2.4.2. PRODUCT LIST
9.2.4.3. STRENGTHS & CHALLENGES
9.2.5. SANTEN PHARMACEUTICAL CO LTD
9.2.5.1. COMPANY OVERVIEW
9.2.5.2. PRODUCTS LIST
9.2.5.3. STRENGTHS & CHALLENGES
9.2.6. NOVARTIS AG
9.2.6.1. COMPANY OVERVIEW
9.2.6.2. PRODUCT LIST
9.2.6.3. STRENGTHS & CHALLENGES
LIST OF TABLES
TABLE 1: MARKET SNAPSHOT - DRY EYE DISEASE MARKET
TABLE 2: JAPAN DRY EYE DISEASE MARKET REGULATORY FRAMEWORK
TABLE 3: JAPAN DRY EYE DISEASE MARKET, BY TYPE, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 4: JAPAN DRY EYE DISEASE MARKET, BY TYPE, FORECAST YEARS, 2024-2032 (IN $ MILLION)
TABLE 5: JAPAN DRY EYE DISEASE MARKET, BY PRODUCT, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 6: JAPAN DRY EYE DISEASE MARKET, BY PRODUCT, FORECAST YEARS, 2024-2032 (IN $ MILLION)
TABLE 7: JAPAN DRY EYE DISEASE MARKET, BY ANTI-INFLAMMATORY DRUGS, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 8: JAPAN DRY EYE DISEASE MARKET, BY ANTI-INFLAMMATORY DRUGS, FORECAST YEARS, 2024-2032 (IN $ MILLION)
TABLE 9: JAPAN DRY EYE DISEASE MARKET, BY DOSAGE, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 10: JAPAN DRY EYE DISEASE MARKET, BY DOSAGE, FORECAST YEARS, 2024-2032 (IN $ MILLION)
TABLE 11: JAPAN DRY EYE DISEASE MARKET, BY DISTRIBUTION CHANNEL, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 12: JAPAN DRY EYE DISEASE MARKET, BY DISTRIBUTION CHANNEL, FORECAST YEARS, 2024-2032 (IN $ MILLION)
TABLE 13: KEY PLAYERS OPERATING IN JAPAN DRY EYE DISEASE MARKET
TABLE 14: LIST OF MERGERS & ACQUISITIONS
TABLE 15: LIST OF PRODUCT LAUNCHES & DEVELOPMENTS
TABLE 16: LIST OF PARTNERSHIPS & AGREEMENTS
TABLE 17: LIST OF BUSINESS EXPANSIONS & DIVESTITURES
LIST OF FIGURES
FIGURE 1: KEY MARKET TRENDS
FIGURE 2: PORTER'S FIVE FORCES ANALYSIS
FIGURE 3: GROWTH PROSPECT MAPPING FOR JAPAN DRY EYE DISEASE MARKET
FIGURE 4: MARKET MATURITY ANALYSIS
FIGURE 5: MARKET CONCENTRATION ANALYSIS
FIGURE 6: VALUE CHAIN ANALYSIS
FIGURE 7: JAPAN DRY EYE DISEASE MARKET, GROWTH POTENTIAL, BY TYPE, IN 2023
FIGURE 8: JAPAN DRY EYE DISEASE MARKET, BY OTC, 2024-2032 (IN $ MILLION)
FIGURE 9: JAPAN DRY EYE DISEASE MARKET, BY PRESCRIPTION, 2024-2032 (IN $ MILLION)
FIGURE 10: JAPAN DRY EYE DISEASE MARKET, GROWTH POTENTIAL, BY PRODUCT, IN 2023
FIGURE 11: JAPAN DRY EYE DISEASE MARKET, BY ANTI-INFLAMMATORY DRUGS, 2024-2032 (IN $ MILLION)
FIGURE 12: JAPAN DRY EYE DISEASE MARKET, GROWTH POTENTIAL, BY ANTI-INFLAMMATORY DRUGS, IN 2023
FIGURE 13: JAPAN DRY EYE DISEASE MARKET, BY CYCLOSPORINE, 2024-2032 (IN $ MILLION)
FIGURE 14: JAPAN DRY EYE DISEASE MARKET, BY CORTICOSTEROID, 2024-2032 (IN $ MILLION)
FIGURE 15: JAPAN DRY EYE DISEASE MARKET, BY OTHER ANTI-INFLAMMATORY DRUGS, 2024-2032 (IN $ MILLION)
FIGURE 16: JAPAN DRY EYE DISEASE MARKET, BY ARTIFICIAL TEARS, 2024-2032 (IN $ MILLION)
FIGURE 17: JAPAN DRY EYE DISEASE MARKET, BY PUNCTAL PLUGS, 2024-2032 (IN $ MILLION)
FIGURE 18: JAPAN DRY EYE DISEASE MARKET, BY SECRETAGOGUES, 2024-2032 (IN $ MILLION)
FIGURE 19: JAPAN DRY EYE DISEASE MARKET, BY OTHER PRODUCTS, 2024-2032 (IN $ MILLION)
FIGURE 20: JAPAN DRY EYE DISEASE MARKET, GROWTH POTENTIAL, BY DOSAGE, IN 2023
FIGURE 21: JAPAN DRY EYE DISEASE MARKET, BY EYE DROPS, 2024-2032 (IN $ MILLION)
FIGURE 22: JAPAN DRY EYE DISEASE MARKET, BY EYE SOLUTIONS, 2024-2032 (IN $ MILLION)
FIGURE 23: JAPAN DRY EYE DISEASE MARKET, BY OINTMENTS, 2024-2032 (IN $ MILLION)
FIGURE 24: JAPAN DRY EYE DISEASE MARKET, BY GELS, 2024-2032 (IN $ MILLION)
FIGURE 25: JAPAN DRY EYE DISEASE MARKET, BY CAPSULES & TABLETS, 2024-2032 (IN $ MILLION)
FIGURE 26: JAPAN DRY EYE DISEASE MARKET, GROWTH POTENTIAL, BY DISTRIBUTION CHANNEL, IN 2023
FIGURE 27: JAPAN DRY EYE DISEASE MARKET, BY HOSPITAL PHARMACIES, 2024-2032 (IN $ MILLION)
FIGURE 28: JAPAN DRY EYE DISEASE MARKET, BY INDEPENDENT PHARMACIES AND DRUG STORES, 2024-2032 (IN $ MILLION)
FIGURE 29: JAPAN DRY EYE DISEASE MARKET, BY ONLINE PHARMACIES/STORES, 2024-2032 (IN $ MILLION)
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security